What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2025-05-14 compared with 2024-11-13 · 149 added, 148 removed, 0 unchanged (100% of the section changed)

Management’s Discussion and Analysis of Financial Condition and Results of Operations

in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Aimei

Health Technology Co., Ltd.

References to our “management” or our “management team” refer to our officers and

directors, and references to our “Sponsor” refer to Aimei Investment Ltd., a Cayman

Islands exempted company with limited liability.

The following discussion and analysis of our financial condition and results

of operations should be read in conjunction with the unaudited financial statements and the notes thereto contained elsewhere in this

Quarterly Report.

Certain information contained in the discussion and analysis set forth below includes forward-looking statements that

involve risks and uncertainties.

Note Regarding Forward-Looking Statements

Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of Securities Act of 1933, as amended

and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are not historical facts, and

involve risks and uncertainties that could cause actual results to differ materially from those expected and projected.

All statements,

other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s

Discussion and Analysis of Financial Condition and Results of Operations” regarding our financial position, business strategy,

and the plans and objectives of management for future operations, are forward-looking statements.

Words such as “expect,”

“believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and

similar words and expressions are intended to identify such forward-looking statements.

Such forward-looking statements relate to future

events or future performance, but reflect management’s current beliefs, based on information currently available.

A number of factors

could cause actual events, performance, or results to differ materially from the events, performance, or results discussed in the forward-looking

For information identifying important factors that could cause actual results to differ materially from those anticipated

in the forward-looking statements, please refer to the Risk Factors section of our final prospectus for our initial public offering (“IPO”)

filed with the U.S.

Securities and Exchange Commission (the “SEC”).

Our securities filings can be accessed on the EDGAR section

of the SEC’s website at www.sec.gov.

Except as expressly required by applicable securities law, we disclaim any intention or obligation

to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

are a blank check company newly incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering

into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with

one or more businesses or entities, which we refer to throughout this report as our initial business combination.

Our efforts to identify

a prospective target business will not be limited to a particular industry or geographic region.

We do not have any specific business

combination under consideration and we have not (nor has anyone on our behalf), directly or indirectly, contacted any prospective target

business or had any substantive discussions, formal or otherwise, with respect to such a transaction with our company.

United Hydrogen Business Combination

June 19, 2024, Aimei Health entered into a definitive Business Combination Agreement (the “Merger Agreement”) for a business

combination with (i) United Hydrogen Group Inc., an exempted company incorporated with limited liability in the Cayman Islands (“United

Hydrogen”), (ii) United Hydrogen Global Inc., an exempted company incorporated with limited liability in the Cayman Islands (“Pubco”),

(iii) United Hydrogen Victor Limited, an exempted company incorporated with limited liability in the Cayman Islands and a wholly-owned

subsidiary of Pubco;

(iv) United Hydrogen Worldwide Limited, an exempted company incorporated with limited liability in the Cayman Islands

and a wholly-owned subsidiary of Pubco ;

and (v) Aimei Investment Ltd., a Cayman Islands

exempted company, in the capacity as, from and after the closing of the transactions contemplated by the Merger Agreement (the “Closing”),

the representative for Aimei Health and its shareholders (the “Sponsor”).

The Merger Agreement may be terminated under certain

customary and limited circumstances prior to the consummation of the Closing, including:

(i) by mutual written consent of Aimei Health

and United Hydrogen;

(ii) by either Aimei Health or United Hydrogen if any law or governmental order (other than a temporary restraining

order) is in effect that permanently restrains, enjoins, makes illegal or otherwise prohibits the mergers and the other transactions

contemplated by the Merger Agreement;

(iii) by either Aimei Health or United Hydrogen if any of the conditions to Closing have not been

satisfied or waived by March 31, 2025;

(iv) by either Aimei Health or United Hydrogen upon a material breach of any representations,

warranties, covenants or other agreements set forth in the Merger Agreement by the other party if such breach gives rise to a failure

of certain closing conditions to be satisfied and cannot or has not been cured within the earlier of 20 days’ following the receipt

of notice from the non-breaching party and the Termination Date;

(v) by either Aimei Health or United Hydrogen if the Aimei Health shareholder

approval is not obtained at its shareholder meeting;

(vi) by Aimei Health if the United Hydrogen shareholder approval is not obtained

within ten (10) business days after the Registration Statement becomes effective;

or (vii) by Aimei Health, if the Reorganization (as

defined in the Merger Agreement) is not completed by December 31, 2024.

The Merger Agreement and related agreements are further described

in our Current Report on Form 8-K filed with the SEC on June 20, 2024.

of Operations

have neither engaged in any operations nor generated any revenue to date.

Our only activities from inception to September 30, 2024 were

organizational activities, those necessary to prepare for and conduct the IPO, and those required to identify and evaluate a target company

for a business combination.

We will not generate any operating revenue until after the completion of our initial business combination,

at the earliest.

We have generated and will continue to generate non-operating income in the form of interest income on cash in bank

and investments held in a trust account established for the benefit of our public shareholders (the “Trust Account”), from

the proceeds derived from the IPO.

We incur expenses as a result of being a public company (for legal, financial reporting, accounting

and auditing compliance), as well as for due diligence expenses.

the nine months ended September 30, 2024, we had a net income of $2,108,102, which consisted of dividend income earned on investments

held in the Trust Account of $2,770,867 offset by formation and operational costs of $662,765.

the three months ended September 30, 2024, we had a net income of $743,510, which consisted of dividend income earned on investments

held in the Trust Account of $943,529 offset by formation and operational costs of $200,019.

the period from April 27, 2023 (inception) to September 30, 2023, we had a net loss of $3,618, which consisted of formation and operational

costs of $3,618.

and Capital Resources

of September 30, 2024, we had $103,559 in our operating bank account, $72,660,715 in our Trust Account, and working capital deficit of

liquidity needs prior to the consummation of the IPO were satisfied through the payment of $25,000 from the Sponsor to cover certain

offering costs on our behalf in exchange for issuance of founder shares, and the borrowing of approximately $210,151 from the Sponsor

under an unsecured promissory note (see “Note 5—Related Party Transactions” in the notes to our unaudited financial

We have repaid the unsecured promissory note in full on December 7, 2023.

Subsequent to the consummation of the IPO, our

liquidity has been satisfied through the net proceeds from the consummation of the IPO and the Private Placement (as defined below) held

outside of the Trust Account.

In addition, in order to finance transaction costs in connection with a business combination, the Sponsor

or an affiliate of the Sponsor, or certain of our officers and directors, may, but are not obligated to, provide the Company Working

Capital Loans (as defined in “Note 5—Related Party Transactions” in the notes to our unaudited financial statements).

As of September 30, 2024, there were no amounts outstanding under the Working Capital Loans.

on the foregoing, management believes that we will have sufficient working capital and borrowing capacity to meet our anticipated cash

needs prior to our initial business combination.

Moreover, we may need to obtain additional financing either to complete our business

combination or because we become obligated to redeem a significant number of our public shares upon completion of our business combination,

in which case we may issue additional securities or incur debt in connection with such business combination.

However, we cannot provide

any assurance that new financing will be available.

Over the time period prior to our initial business combination, we will be using

the funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial business

combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target

business to merge with or acquire, and structuring, negotiating and consummating the business combination.

Concern Consideration

connection with our assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15,

“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined

that if we are unsuccessful in consummating an initial business combination within the prescribed period of time from the closing of

our IPO, the requirement that we cease all operations, redeem the public shares, and thereafter liquidate and dissolve, raises substantial

doubt about the ability to continue as a going concern.

The financial statements do not include any adjustments that might result from

the outcome of this uncertainty.

The accompanying unaudited financial statements have been prepared in conformity with generally accepted

accounting principles in the United States of America, which contemplate the continuation of our Company as a going concern.

Sheet Financing Arrangements

have no obligations, assets, or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2024.

not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as

variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.

not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments

of other entities, or purchased any non-financial assets.

do not have any long-term debt, capital lease obligations, operating lease obligations, or long-term liabilities.

The underwriter is

entitled to a deferred fee of one percent (1.0%) of the gross proceeds of the IPO upon closing of a business combination, or $690,000.

The deferred fee will be paid in cash upon the closing of the business combination from the amounts held in the Trust Account (as defined

below), subject to the terms of the underwriting agreement.

Accounting Policies

preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United

States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure

of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported.

results could materially differ from those estimates.

As of September 30, 2024, there were no critical accounting policies or estimates.

Accounting Standards

does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material

effect on our audited financial statements.

Quantitative and Qualitative Disclosures About Market Risk .

a smaller reporting company, we are not required to provide this information.

Management’s Discussion and Analysis

of Financial Condition and Results of Operations

References in this report (the “Quarterly

Report”) to “we,” “us” or the “Company” refer to Aimei Health Technology Co., Ltd.

to our “management” or our “management team” refer to our officers and directors, and references to our “Sponsor”

refer to Aimei Investment Ltd., a Cayman Islands exempted company with limited liability.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited

financial statements and the notes thereto contained elsewhere in this Quarterly Report.

Certain information contained in the discussion

and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking

statements” within the meaning of Section 27A of Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act

of 1934, as amended (the “Exchange Act”), that are not historical facts, and involve risks and uncertainties that could cause

actual results to differ materially from those expected and projected.

All statements, other than statements of historical fact included

in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial

Condition and Results of Operations” regarding our financial position, business strategy, and the plans and objectives of management

for future operations, are forward-looking statements.

Words such as “expect,” “believe,” “anticipate,”

“intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify

such forward-looking statements.

Such forward-looking statements relate to future events or future performance, but reflect management’s

current beliefs, based on information currently available.

A number of factors could cause actual events, performance, or results to differ

materially from the events, performance, or results discussed in the forward-looking statements.

For information identifying important

factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to

the Risk Factors section of our final prospectus for our initial public offering (“IPO”) filed with the U.S.

Securities and

Exchange Commission (the “SEC”).

Our securities filings can be accessed on the EDGAR section of the SEC’s website at

Except as expressly required by applicable securities law, we disclaim any intention or obligation to update or revise any

forward-looking statements whether as a result of new information, future events, or otherwise.

We are a blank check company newly incorporated as

a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition,

share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, which we refer

to throughout this report as our initial business combination.

Our efforts to identify a prospective target business will not be limited

to a particular industry or geographic region.

We do not have any specific business combination under consideration and we have not (nor

has anyone on our behalf), directly or indirectly, contacted any prospective target business or had any substantive discussions, formal

or otherwise, with respect to such a transaction with our company.

Proposed United Hydrogen Business Combination

On June 19, 2024, Aimei Health entered into a definitive

Business Combination Agreement (the “Merger Agreement”) for a business combination with (i) United Hydrogen Group Inc., an

exempted company incorporated with limited liability in the Cayman Islands (“United Hydrogen”), (ii) United Hydrogen Global

Inc., an exempted company incorporated with limited liability in the Cayman Islands (“Pubco”), (iii) United Hydrogen Victor

Limited, an exempted company incorporated with limited liability in the Cayman Islands and a wholly-owned subsidiary of Pubco;

Hydrogen Worldwide Limited, an exempted company incorporated with limited liability in the Cayman Islands and a wholly-owned subsidiary

and (v) Aimei Investment Ltd., a Cayman Islands exempted company, in the capacity

as, from and after the closing of the transactions contemplated by the Merger Agreement (the “Closing”), the representative

for Aimei Health and its shareholders (the “Sponsor”).

The Merger Agreement may be terminated under certain customary and

limited circumstances prior to the consummation of the Closing, including:

(i) by mutual written consent of Aimei Health and United Hydrogen;

(ii) by either Aimei Health or United Hydrogen if any law or governmental order (other than a temporary restraining order) is in effect

that permanently restrains, enjoins, makes illegal or otherwise prohibits the mergers and the other transactions contemplated by the Merger

(iii) by either Aimei Health or United Hydrogen if any of the conditions to Closing have not been satisfied or waived by March

(iv) by either Aimei Health or United Hydrogen upon a material breach of any representations, warranties, covenants or other

agreements set forth in the Merger Agreement by the other party if such breach gives rise to a failure of certain closing conditions to

be satisfied and cannot or has not been cured within the earlier of 20 days’ following the receipt of notice from the non-breaching

party and the Termination Date;

(v) by either Aimei Health or United Hydrogen if the Aimei Health shareholder approval is not obtained

at its shareholder meeting;

(vi) by Aimei Health if the United Hydrogen shareholder approval is not obtained within ten (10) business

days after the Registration Statement becomes effective;

or (vii) by Aimei Health, if the Reorganization (as defined in the Merger Agreement)

is not completed by December 31, 2024.

The Merger Agreement and related agreements are further described in our Current Report on Form

8-K filed with the SEC on June 20, 2024.

Results of Operations

We have neither engaged in any operations nor generated

any revenue to date.

Our only activities from inception to March 31, 2025 were organizational activities, those necessary to prepare for

and conduct the IPO, and those required to identify and evaluate a target company for a business combination.

We will not generate any

operating revenue until after the completion of our initial business combination, at the earliest.

We have generated and will continue

to generate non-operating income in the form of interest income on cash in bank and cash held in a trust account established for the benefit

of our public shareholders (the “Trust Account”), from the proceeds derived from the IPO.

We incur expenses as a result of

being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three months ended March 31, 2025, we had

a net income of $184,662, which consisted of interest income earned on assets held in the Trust Account of $598,076, offset by formation

and operational costs of $413,414.

Liquidity and Capital Resources

As of March 31, 2025, we had $7,345 in our operating

bank account, $43,594,825 in our Trust Account, and working capital deficit of approximately $1,677,724

Our liquidity needs prior to the consummation of the

IPO were satisfied through the payment of $25,000 from the Sponsor to cover certain offering costs on our behalf in exchange for issuance

of founder shares.

Subsequent to the consummation of the IPO, our liquidity has been satisfied through the net proceeds from the consummation

of the IPO and the Private Placement (as defined below) held outside of the Trust Account.

In addition, in order to finance transaction

costs in connection with a business combination, the Sponsor or an affiliate of the Sponsor, or certain of our officers and directors,

may, but are not obligated to, provide the Company Working Capital Loans (as defined in “Note 5—Related Party Transactions”

in the notes to our financial statements).

As of March 31, 2025, there were no amounts outstanding under the Working Capital Loans.

Based on the foregoing, management believes that we

will have sufficient working capital and borrowing capacity to meet our anticipated cash needs prior to our initial business combination.

Moreover, we may need to obtain additional financing either to complete our business combination or because we become obligated to redeem

a significant number of our public shares upon completion of our business combination, in which case we may issue additional securities

or incur debt in connection with such business combination.

However, we cannot provide any assurance that new financing will be available.

Over the time period prior to our initial business combination, we will be using the funds held outside of the Trust Account for paying

existing accounts payable, identifying and evaluating prospective initial business combination candidates, performing due diligence on

prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring,

negotiating and consummating the business combination.

Going Concern Consideration

In connection with our assessment of going concern

considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an

Entity’s Ability to Continue as a Going Concern,” management has determined that if we are unsuccessful in consummating an

initial business combination within the prescribed period of time from the closing of our IPO, the requirement that we cease all operations,

redeem the public shares, and thereafter liquidate and dissolve, raises substantial doubt about the ability to continue as a going concern

within one year after the date that the financial statements are issued.

The financial statements do not include any adjustments that

might result from the outcome of this uncertainty.

The accompanying unaudited financial statements have been prepared in conformity with

generally accepted accounting principles in the United States of America, which contemplate the continuation of our Company as a going

Off-Balance Sheet Financing Arrangements

We have no obligations, assets, or liabilities, which

would be considered off-balance sheet arrangements as of March 31, 2025.

We do not participate in transactions that create relationships

with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established

for the purpose of facilitating off-balance sheet arrangements.

We have not entered into any off-balance sheet financing arrangements,

established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations

We do not have any long-term debt, capital lease obligations,

operating lease obligations, or long-term liabilities.

The underwriter is entitled to a deferred fee of one percent (1.0%) of the gross

proceeds of the IPO upon closing of a business combination, or $690,000.

The deferred fee will be paid in cash upon the closing of the

business combination from the amounts held in the Trust Account (as defined below), subject to the terms of the underwriting agreement.

Critical Accounting Policies

The preparation of financial statements and related

disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates

and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date

of the financial statements, and income and expenses during the periods reported.

Actual results could materially differ from those estimates.

As of March 31, 2025, there were no critical accounting policies or estimates.

Recent Accounting Standards

Management does not believe that any recently issued,

but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on our audited financial statements.

Quantitative and Qualitative Disclosures

About Market Risk .

As a smaller reporting company, we are not required

to provide this information.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis